Cross-subunit interactions that stabilize open states mediate gating in NMDA receptors.

NMDA receptor energy landscape mutant cycle analysis single molecule targeted molecular dynamics

Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
12 01 2021
Historique:
entrez: 1 1 2021
pubmed: 2 1 2021
medline: 8 5 2021
Statut: ppublish

Résumé

NMDA receptors are excitatory channels with critical functions in the physiology of central synapses. Their activation reaction proceeds as a series of kinetically distinguishable, reversible steps, whose structural bases are currently under investigation. Very likely, the earliest steps include glutamate binding to glycine-bound receptors and subsequent constriction of the ligand-binding domain. Later, three short linkers transduce this movement to open the gate by mechanical pulling on transmembrane helices. Here, we used molecular and kinetic simulations and double-mutant cycle analyses to show that a direct chemical interaction between GluN1-I642 (on M3 helix) and GluN2A-L550 (on L1-M1 linker) stabilizes receptors after they have opened and thus represents one of the structural changes that occur late in the activation reaction. This native interaction extends the current decay, and its absence causes deficits in charge transfer by GluN1-I642L, a pathogenic human variant.

Identifiants

pubmed: 33384330
pii: 2007511118
doi: 10.1073/pnas.2007511118
pmc: PMC7812756
pii:
doi:

Substances chimiques

Receptors, N-Methyl-D-Aspartate 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NINDS NIH HHS
ID : R01 NS052669
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS097016
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS108750
Pays : United States

Informations de copyright

Copyright © 2020 the Author(s). Published by PNAS.

Déclaration de conflit d'intérêts

The authors declare no competing interest.

Références

Nat Rev Neurosci. 2017 Mar 17;18(4):236-249
pubmed: 28303017
J Mol Graph. 1996 Dec;14(6):354-60, 376
pubmed: 9195488
Biophys J. 2017 Jun 20;112(12):2589-2601
pubmed: 28636915
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
pubmed: 8744570
Mol Pharmacol. 2013 May;83(5):1045-56
pubmed: 23455314
PLoS Genet. 2017 Jan 17;13(1):e1006536
pubmed: 28095420
Science. 2017 Mar 24;355(6331):
pubmed: 28232581
J Neurophysiol. 2012 Dec;108(11):3105-15
pubmed: 22993263
Philos Trans R Soc Lond B Biol Sci. 1982 Dec 24;300(1098):1-59
pubmed: 6131450
J Biol Chem. 2012 Oct 19;287(43):36071-80
pubmed: 22948148
Brain. 2019 Jan 1;142(1):80-92
pubmed: 30544257
J Gen Physiol. 2020 Apr 6;152(4):
pubmed: 32221541
Nat Neurosci. 2003 May;6(5):476-83
pubmed: 12679783
Curr Opin Physiol. 2018 Apr;2:114-122
pubmed: 29978141
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
J Physiol. 1983 Nov;344:605-23
pubmed: 6317854
Nat Neurosci. 2014 Jul;17(7):914-22
pubmed: 24859202
J Comput Chem. 2005 Dec;26(16):1781-802
pubmed: 16222654
J Neurosci. 2016 Mar 2;36(9):2617-22
pubmed: 26937003
J Neurosci. 2009 Sep 30;29(39):12045-58
pubmed: 19793963
Nature. 2014 Jul 10;511(7508):191-7
pubmed: 25008524
Nature. 2018 Apr;556(7702):515-519
pubmed: 29670280
J Am Chem Soc. 2014 Sep 17;136(37):12998-3005
pubmed: 25148304
Pharmacol Rev. 2010 Sep;62(3):405-96
pubmed: 20716669
Front Mol Neurosci. 2018 Apr 06;11:113
pubmed: 29681798
Curr Opin Neurobiol. 2001 Jun;11(3):327-35
pubmed: 11399431
J Neurosci. 2008 Feb 13;28(7):1546-56
pubmed: 18272676
Science. 1992 Nov 6;258(5084):1007-11
pubmed: 1279803
J Physiol. 2015 Jan 1;593(1):83-95
pubmed: 25556790
J Gen Physiol. 2014 Nov;144(5):441-55
pubmed: 25311637
J Neurosci. 2009 May 27;29(21):6819-27
pubmed: 19474309
Science. 1992 May 22;256(5060):1217-21
pubmed: 1350383
J Gen Physiol. 2015 Jun;145(6):513-27
pubmed: 25964432
J Physiol. 2020 Aug;598(15):3071-3083
pubmed: 32468591
Mol Pharmacol. 2005 Oct;68(4):1148-55
pubmed: 16033953
Cell. 1984 Oct;38(3):835-40
pubmed: 6488318
Curr Opin Pharmacol. 2015 Feb;20:73-82
pubmed: 25498981
J Biol Chem. 2016 Jul 29;291(31):16175-85
pubmed: 27226581
Biophys J. 2018 Sep 4;115(5):841-852
pubmed: 30029773
Science. 2014 May 30;344(6187):992-7
pubmed: 24876489
J Neurosci. 2013 Jul 17;33(29):12052-66
pubmed: 23864691
Nature. 2004 Aug 12;430(7001):790-3
pubmed: 15306812
Cell. 2018 Nov 29;175(6):1520-1532.e15
pubmed: 30500536
Nature. 2016 May 02;534(7605):63-8
pubmed: 27135925
J Gen Physiol. 2012 Sep;140(3):267-77
pubmed: 22891278

Auteurs

Gary J Iacobucci (GJ)

Department of Biochemistry, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, SUNY, Buffalo, NY 14203.

Han Wen (H)

Department of Physics, College of Arts and Sciences, University at Buffalo, SUNY, Buffalo, NY 14260.

Matthew Helou (M)

Department of Biochemistry, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, SUNY, Buffalo, NY 14203.

Beiying Liu (B)

Department of Biochemistry, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, SUNY, Buffalo, NY 14203.

Wenjun Zheng (W)

Department of Physics, College of Arts and Sciences, University at Buffalo, SUNY, Buffalo, NY 14260 wjzheng@buffalo.edu popescu@buffalo.edu.

Gabriela K Popescu (GK)

Department of Biochemistry, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, SUNY, Buffalo, NY 14203; wjzheng@buffalo.edu popescu@buffalo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH